Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients

Clinical Cancer Research

Volumn 2, Issue 7, 1996, Pages 1191-1198

  Gasparini, Giampietro ^a   Fox, Stephen B ^b   Verderio, Paolo ^c   Bonoldi, Emanuela ^a   Bevilacqua, Pierantonio ^a   Boracchi, Patrizia ^c   Dante, Stefania ^a   Marubini, Ettore ^c   Harris, Adrian L ^b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR VOLUME;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0029889029     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Fisher, B., Redmond, C., Brown, A., Wickerham, D. L., Wolkman, N., Allegra, J., Escher, G., Lippman, M. E., Saslov, E., and Wittliff, J. Influence of tumor estrogen and progesterone levels on the response to tamoxifen and chemotherapy in primary breast cancer. J. Clin. Oncol., 1: 227-241, 1983
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 1-15, 1992.
3. Mason, B H., Holdaway, I. M., Mullins, P. R., Yee, L. H., and Kay, R G. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res., 43: 2985-2990, 1983.
4. Clark, G. M., McGuire, W. L., Hubay, C. A., Person, O. H., and Marshall, J. S. Progesterone receptor as a prognostic factor in stage II breast cancer. N. Engl. J. Med., 309: 1343-1347, 1983.
5. Foekens, J. A., van Putten, W L. J., Portengen, H., de Koning, H. Y. W. C. M., Thrion, B., Alexieva-Figush, J., and Klijn, J. G. M. Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J. Clin. Oncol., 11: 899-908, 1993.
6. Wright, C , Nicholson, S., Angus, B., Sainsbury, J. R. C., Farndon, J., Cairns, J., Harris, A. L., and Horne, C. H N. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer, 65: 118-121, 1992.
7. Gasparini, G., Barbareschi, M., Doglioni, C., Dalla Palma, P., Mauri, F. A., Boracchi, P., Bevilacqua, P., Caffo, O., Morelli, L , Verderio, P., Pezzella, F., and Harris, A. L. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res., 1: 189-198, 1995.
8. Nicholson, S., Halcrow, P., Farndon, J. R., Sainsbury, J. R. C., Chambers, I., and Harris, A. L. Expression of epidermal growth factor receptor associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet. 333: 182-185, 1989.
9. Gasparini, G., Pozza, F., and Harris, A. L. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 1206-1219, 1993.
10. Dickson, R. B., and Lippman, M. E. Growth factors in breast cancer. Endocrine Rev., 16: 559-589, 1995.
11. Kolch, W., Martiny-Baron, G., Kieser, A., and Marmè, D. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res. Treat., 36: 139-155, 1995.
12. Macaulay, V. M., Fox, S. B , Zhang, H., Whitehouse, R. M., Leek, R. D., Gatter, K. C., Bicknell, R., and Harris, A. L Breast cancer angiogenesis and tamoxifen resistance. Endocr.-Rel Cancer, 2: 97-103, 1995.
13. Kurebayashi, J., McLeskey, S. W., Johnson, M. D., Lippman, M. E., Dickson, R B., and Kern, F. G. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and Lac Z. Cancer Res., 53: 2178-2187, 1993.
14. McLeskey, S. W., Kurebayashi, J., Honig, S. F., Zwiebel, J., Lippman, M. E , Dickson, R. B., and Kern, F. G. Fibroblast growth factor-4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovariectomized or tamoxifen-treated athymic nude mice. Cancer Res., 53: 2168-2177, 1993.
15. Gasparini, G., Barbareschi, M., Boracchi, P., Verderio, P., Caffo, O., Meli, S., Dalla Palma, P., Marubini, E., and Bevilacqua, P. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J. Sci. Am., 1: 131-141, 1995.
16. Axelsson, K., Ljung, B-M. E., Moore, D. H., II, Thor, A. D., Chew, K. L., Edgerton, S. M., Smith, H. S., and Mayall, B. H. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma, J. Natl. Cancer Inst., 87. 997-1008, 1995.
17. Vermeulen, P. B., Libura, J., Libura, M., Hellmans, P. W. J., Van Mark, E., Van Oosterom, A. T , and Dirix, L. Y. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst., 87: 1797-1798, 1995.
18. Fox, S. B., Gatter, K. C., Altman, D. G., Leek, R. D., and Harris, A. L. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst., 87: 1798-1799, 1995.
19. Gasparini, G. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst., 87: 1799-1801, 1995.
20. Axelsson, K., Ljung, B-M. E., Chew, K. L., Mayall, B. H., Moore, D. H , II, Smith, H. S., Thor, A. D., and Edgerton, S. M. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst., 87: 1801-1802, 1995.
21. Veronesi, U., Saccozzi, R., Del Vecchio, M., Banfi, A., Clemente, C., De Lena, M., Gallus, G., Greco, M., Luini, A., Marubini, E., Muscolino, G., Rilke, F., Salvadori, B., Zecchini, A., and Zucali, R. Comparing radical mastectomy with quadrantectomy, axillary and radiotherapy in patients with small cancers of the breast. N. Engl. J. Med., 305: 6-11, 1981.
22. Fisher, E. R , Gregorio, R. M., and Fisher, B. The pathology of invasive breast cancer: a syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer (Phila.), 36: 1-85, 1975.
23. Elston, C. W., and Ellis, I. Q. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410, 1991.
24. Horak, E. R , Leek, R., Klenk, N., LeJeune, S., Smith, K., Stuart, N., Greenall, M., Stepniewska, K., and Harris, A L. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet, 340: 1120-1124, 1992.
25. Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbareschi, M., Boracchi, P., Marubini, E., and Pozza, F. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol., 12: 454-466, 1994.
26. Fox, S. B., Leek, R. D., Weeks, M. P., Whitehouse, R. M., Gatter, K C., and Harris, A. L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J. Pathol., 177: 275-283, 1995.
27. Altman, D. G., Lausen, B., Saurbrei, W., and Schumacher, M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors J. Natl. Cancer. Inst., 86: 829-835, 1994.
28. Durrleman, S., and Simon, R. Flexible regression models with cubic splines. Stat. Med., 8: 551-561, 1989.
29. Harrell, F. E., Califf, R. M., Pryor, D. B., Leek, K. L., and Rosati, R. A Evaluating the yield of medical tests. J. Am. Med. Assoc., 247: 2543-2548, 1982.
30. Gasparini, G., Bonoldi, E., Viale, G., Verderio, P., Boracchi, P., Panizzoni, G. A., Radaelli, U., Di Bacco, A., Guglielmi, R. B., and Bevilacqua, P. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int. J. Cancer, in press, 1996.
31. Folkman, J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res. Treat., 36: 109-118, 1995.
32. Zhang, H-T., Craft, P., Scott, P. A. E., Ziche, M., Weich, H A , Harris, A. L., and Bicknell, R. Enhancement of tumor growth and vascular density by transfection of vascular endothelial growth factor into MCF-7 human breast carcinoma cells. J. Natl. Cancer Inst., 87: 213-219, 1995.
33. Weinstat-Saslow, D. L., Zabrenetzky, V. S , Van Houtte, K., Frazier, W. A., Roberts, D. D., and Steeg, P. S. Transfection of thrombospondin-1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis Cancer Res., 54: 6504-6511, 1994.
34. Volpert, O. V., Stellmach, V., and Bouck, N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res. Treat., 36: 119-126, 1995.
35. Gasparini, G., and Harris, A. L. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. Clin. Oncol., 13: 765-782, 1995.
36. Gasparini, G. Biological and clinical role of angiogenesis in breast cancer Breast Cancer Res Treat., 36: 103-107, 1995.
37. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., Senger, D. R., Connolly, J. L., and Schnitt, S. J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol., 26: 86-91, 1995.
38. Toi, M., Inada, K., Hoshina, S., Suzuki, H , Kondo, S., and Tominaga, T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin. Cancer Res., 1: 961-964, 1995.
39. Shweiki, D., Itin, A., Neufeld, G , Gitay-Goren, H., and Keshet, E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J. Clin. Invest., 91: 2235-2243, 1993.
40. Coltrera, M. D., Wang, J., Portes, P. L., and Gown, A. M. Expression of platelet-derived growth factor β-chain and the platelet-derived growth factor receptor β subunit in human breast tissue and breast carcinoma. Cancer Res., 55: 2703-2708, 1995.
41. Arteaga, C. L., Carty-Dugger, T., Moses, H. L., Hurd, S. D., and Pietenpol, J. A. Transforming growth factor β1 can induce estrogen-independent tumongenicity of human breast cancer cells in athymic mice. Cell Growth & Differ , 4: 193-201, 1993.
42. Gagliardi, A., and Collins, D. C. Inhibition of angiogenesis by antiestrogens. Cancer Res., 53: 533-535, 1993.
43. Noguchi, S., Motomura, K., Inaji, H., Imaoka, S., and Koyama, H. Down-regulation of transforming growth factor-α by tamoxifen in human breast cancer. Cancer (Phila.), 72: 131-136, 1993.
44. Rak, J. W., Hegmann, E J., Lu, C. and Kerbel, R. S. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J. Cell. Physiol., 159: 245-255, 1994.
45. Folkman, J. Tumor angiogenesis and tissue factor. Nature Med., 2: 167-168, 1996.
46. Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., and Nuseir, N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature (Lond.), 329: 630-632, 1987.